Anti-PD-1 monoclonal antibodies
Other names: anti-programmed cell death-1 (PD-1) monoclonal antibodies, immune checkpoint inhibitors, programmed death-ligand 1 (PD-L1) blocking antibodies
What are Anti-PD-1 monoclonal antibodies?
List of Anti-PD-1 monoclonal antibodies
View by Brand | Generic
Drug Name | Avg. Rating | Reviews |
---|---|---|
Keytruda (Pro) Generic name: pembrolizumab |
178 reviews | |
Opdivo (Pro) Generic name: nivolumab |
73 reviews | |
Libtayo (Pro) Generic name: cemiplimab |
3 reviews | |
Tecentriq (Pro) Generic name: atezolizumab | 1 review | |
Jemperli (Pro) Generic name: dostarlimab | No reviews | |
Imfinzi (Pro) Generic name: durvalumab | No reviews | |
Bavencio (Pro) Generic name: avelumab | No reviews | |
For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). |
See also
Medical conditions associated with anti-PD-1 monoclonal antibodies:
- Alveolar Soft Part Sarcoma
- Basal Cell Carcinoma
- Biliary Tract Tumor
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Endometrial Cancer
- Esophageal Carcinoma
- Gastric Cancer
- Head and Neck Cancer
- Hepatocellular Carcinoma
- Hodgkin's Lymphoma
- Malignant Pleural Mesothelioma
- Melanoma
- Melanoma, Metastatic
- Merkel Cell Carcinoma
- Non-Small Cell Lung Cancer
- Primary Mediastinal Large B-cell Lymphoma
- Renal Cell Carcinoma
- Small Cell Lung Cancer
- Solid Tumors
- Squamous Cell Carcinoma
- Stomach Cancer
- Urothelial Carcinoma
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.